News & Updates

Treatment with tapinarof cream 1% once daily demonstrates significant efficacy with a favourable safety profile among adults and children with moderate-to-severe atopic dermatitis (AD), a study has shown.

Use of dupilumab effectively lowers the risk of atopic march progression as opposed to conventional immunomodulatory therapies in paediatric patients with atopic dermatitis (AD), reports a recent study.

For patients with severe alopecia areata who achieved meaningful hair regrowth with 1-year course of baricitinib, subsequent discontinuation appears to reverse treatment gains, highlighting the need for ongoing therapy.

High dietary consumption of trans fatty acids and saturated fatty acids appears to play some role in atopic dermatitis (AD) flare-ups among Chinese adults from Singapore and Malaysia, according to a large study.

Pathological response rates are high for neoadjuvant dabrafenib plus trametinib among patients with stage III melanoma, but recurrence-free survival (RFS) rates are low, reports a study.

A 16-week dosing interval for the IL-23 inhibitor guselkumab appears to sufficiently keep psoriasis controlled among patients who have achieved complete skin clearance shortly after starting standard treatment with the drug, according to the phase IIIb GUIDE clinical trial.